The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Generation of Species Cross-reactive Aptamers Using “Toggle” SELEX
Open accessAbstract
Species cross-reactivity facilitates the preclinical evaluation of potentially therapeutic molecules in animal models. Here we describe an in vitro selection strategy in which RNA ligands (aptamers) that bind both human and porcine thrombin were selected by "toggling" the protein target between human and porcine thrombin during alternating rounds of selection. The "toggle" selection process yielded a family of aptamers, all of which bound both human and porcine thrombin with high affinity. Toggle-25, a characteristic member, inhibited two of thrombin's most important functions: plasma clot formation and platelet activation. If appropriate targets are available, the toggle strategy is a simple measure that promotes cross-reactivity and may be generalizable to related proteins of the same species as well as to other combinatorial library screening strategies. This strategy should facilitate the isolation of ligands with needed properties for gene therapy and other therapeutic and diagnostic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Mathews, D. H., Sabina, J., Zuker, M., & Turner, D. H. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2700 · Cited by 3,795 · cited 1×
“Application of RNA-folding algorithms to the predominant sequence family suggested a common stemloop structure that incorporated the conserved sequence motif [19].”
BackgroundThrombin signalling and protease-activated receptors
Coughlin, S. R. (2000) · Nature · doi:10.1038/35025229 · Cited by 2,482
Selection of single-stranded DNA molecules that bind and inhibit human thrombin
Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H., & Toole, J. J. (1992) · Nature · doi:10.1038/355564a0 · Cited by 2,469
Stenberg, P. E., McEver, R. P., Shuman, M. A., Jacques, Y. V., & Bainton, D. F. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.3.880 · Cited by 871
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes
Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991) · Science · doi:10.1126/science.1857967 · Cited by 463
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
Sullenger, B. A., Gallardo, H. F., Ungers, G. E., & Gilboa, E. (1990) · Cell · doi:10.1016/0092-8674(90)90455-n · Cited by 443
Self-citationMann, M. J., Whittemore, A. D., Donaldson, M. C., Belkin, M., Conte, M. S., Polak, J. F., Orav, E. J., Ehsan, A., Dell'Acqua, G., & Dzau, V. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)09405-2 · Cited by 402
Cited by
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,430
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Self-citationCurrent approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
Aptamers come of age – at last
Bunka, D. H. J., & Stockley, P. G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1458 · Cited by 695
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
Self-citationRNA aptamers as reversible antagonists of coagulation factor IXa
Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512
Self-citationYu, H., Alkhamis, O., Canoura, J., Liu, Y., & Xiao, Y. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202008663 · Cited by 492
Challenges and Opportunities for Small Molecule Aptamer Development
McKeague, M., & DeRosa, M. C. (2012) · Journal of Nucleic Acids · doi:10.1155/2012/748913 · Cited by 466
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Nucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects
Mascini, M., Palchetti, I., & Tombelli, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201006630 · Cited by 374
Antidote-mediated control of an anticoagulant aptamer in vivo
Rusconi, C. P., Roberts, J. D., Pitoc, G. A., Nimjee, S. M., White, R. R., Quick, G., Scardino, E., Fay, W. P., & Sullenger, B. A. (2004) · Nature Biotechnology · doi:10.1038/nbt1023 · Cited by 339
Self-citationEvolutionary landscapes for the acquisition of new ligand recognition by RNA aptamers
Held, D. M., Travis Greathouse, S., Agrawal, A., & Burke, D. H. (2003) · Journal of Molecular Evolution · doi:10.1007/s00239-003-2481-y · Cited by 41
Metadata
- Authors
- White, R., Rusconi, C., Scardino, E., Wolberg, A., Lawson, J., Hoffman, M., & Sullenger, B.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 4
- Issue
- 6
- Pages
- 567-573
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2314045451
- Cited by
- 284
- References
- 30
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.